Raf inhibitors such as vemurafenib, dabrafenib, and GDC-0879 are promising for the treatment of melanoma, CRC, thyroid and other solid cancers and leukemias/lymphomas/myelomas which have mutations at BRAF V600E. This evidence concerns the gene BRAF and plasma cell myeloma.